Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes

European Heart Journal

Volumn 25, Issue 4, 2004, Pages 313-321

  Roe, Matthew T ^a   Mahaffey, K W ^a   Kilaru, R ^a   Alexander, J H ^a   Akkerhuis, K M ^b   Simoons, M L ^b   Harrington, R A ^a   Tardiff, B E ^a   Granger, C B ^a   Ohman, E M ^a   Moliterno, D J ^f   Lincoff, A M ^c   Armstrong, P W ^d   Van De Werf, F ^e   Califf, R M ^a   Topol, E J ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Acute coronary syndromes; Biomarkers; Creatine kinase; Percutaneous coronary interventions; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE MB; HEPARIN;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; ST SEGMENT; STATISTICAL ANALYSIS;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; FEMALE; HOSPITAL MORTALITY; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 10744221110     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.12.009     Document Type: Article

References (28)

1. Califf RM, Abdelmeguid AE, Kuntz RE et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
2. Harrington RA. Cardiac enzyme elevations after percutaneous coronary intervention: myonecrosis, the coronary microcirculation, and mortality. J Am Coll Cardiol 2000;35:1142-4.
3. Holmes DR Jr, Berger PB. Troponisms, necrosettes, enzyme leaks, creatine phosphokinase bumps, and infarclets: what's behind this new lexicon and what does it add? Circulation 2001;104:627-9.
4. Kong TQ, Davidson CJ, Meyers SN et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
5. Abdelmeguid AE, Topol EJ, Whitlow PL et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
6. Tardiff BE, Califf RM, Tcheng JE et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 1999;33:88-96.
7. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-80.
8. Harrington RA, Califf RM, Holmes DR Jr et al. Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-1). Am Heart J 1999;137:227-33.
9. Thel MC, Califf RM, Tardiff BE et al. Timing and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Am J Cardiol 2000;85:427-35.
10. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
11. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
12. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
13. Mahaffey KW, Harrington RA, Akkerhuis M et al. Disagreements between a central clinical events committee and site investigator assessments of myocardial infarction end points in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardlovasc Med 2001;2:187-94.
14. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105:316-21.
15. Alpert JS, Thygesen K. Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-69.
16. Smith PL. Splines as a useful and convenient statistical tool. Am Statistician 1979;33:57-62.
17. Boersma E, Pieper KS, Steyerberg EW et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation 2000;101:2557-67.
18. Stone GW, Mehran R, Dangas G et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642-7.
19. Riccardi MJ, Wu E, Davidson CJ et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-3.
20. Kanaparti PK, Brown DL. Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol 2000;86:619-22.
21. Mehran R, Dangas G, Mintz GS et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation 2000;101:604-10.
22. Sacuedo JF, Mehran R, Dangas G et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000;35:1134-41.
23. Ellis SG, Chew D, Chan A et al. Death following creatine kinase-MB elevation after coronary intervention. Circulation 2002;106:1205-10.
24. Brener SJ, Lytle BW, Schneider JP et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002;40:1961-7.
25. Akkerhuis KM, Alexander JH, Tardiff BE et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6.
26. Cantor WJ, Newby LK, Christenson RH et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;89:1738-44.
27. Alexander JH, Sparapani RA, Mahaffey KW et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. JAMA 2000;283:347-53.
28. Morales PA., Heuser RR. Embolic protection devices. J Interv Cardiol 2002;15:485-90.